Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)

National Cancer Institute (NCI) and National Institute on Drug Abuse (NIDA)

Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)

“Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI), National Institute on Drug Abuse (NIDA), and National Center for Complementary and Integrative Health (NCCIH) invite Cooperative Agreement (U01) applications that propose prospective research studies to assess the benefits and harms of cannabis and cannabinoid use among adult cancer patients during active treatment. NCI, NIDA, and NCCIH are seeking well-designed prospective cohort studies of cancer patients with solid or hematologic tumors currently receiving treatment. Studies are expected to compare cancer patients who use cannabis/cannabinoids with cancer patients that do not use cannabis and/or cannabinoids.

Research studies including diverse populations by age, sex, race/ethnicity, tumor types, and/or geography and propose population-based recruitment strategies using cancer registries are strongly encouraged.

This FOA is published in parallel with RFA-CA-22-053 “”Coordinating Center for Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed).” New prospective studies and the coordinating center funded under these FOAs will work together with NIH program staff.”

DEADLINE : Open Date (Earliest Submission Date): January 17, 2023 Letter of Intent Due Date(s): 30 days prior to the application due date

Arua Coe-NCD grants and funding logo

Leave a Reply

Your email address will not be published. Required fields are marked *